Periodontal disease and type 2 diabetes mellitus: Is the HMGB1-RAGE axis the missing link?

Medical Hypotheses

Volumn 79, Issue 4, 2012, Pages 452-455

  Morimoto Yamashita, Yoko ^a   Ito, Takashi ^a   Kawahara, Ko Ichi ^a,b   Kikuchi, Kiyoshi ^c   Tatsuyama Nagayama, Shoko ^a   Kawakami Morizono, Yoshiko ^a   Fijisawa, Mari ^a   Miyashita, Keiko ^a   Emoto, Makiko ^a   Torii, Mitsuo ^a   Tokuda, Masayuki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b OSAKA INSTITUTE OF TECHNOLOGY   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTITIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION;

CELL LINE; CYTOKINES; DIABETES MELLITUS, TYPE 2; EPITHELIAL CELLS; GINGIVA; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; MODELS, BIOLOGICAL; PERIODONTAL DISEASES; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84865975819     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.06.020     Document Type: Article

References (45)

1. Socransky S.S., Haffajee A.D., Cugini M.A., Smith C., Kent R.L. Microbial complexes in subgingival plaque. J Clin Periodontol 1998, 25:134-144.
2. Graves D.T., Jiang Y., Genco C. Periodontal disease: bacterial virulence factors, host response and impact on systemic health. Curr Opin Infect Dis 2000, 13:227-232.
3. Verweij C.L. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. Ann Rheum Dis 1999, 58(Suppl 1):120-126.
4. Graves D.T., Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 2003, 74:391-401.
5. Stashenko P., Dewhirst F.E., Peros W.J., Kent R.L., Ago J.M. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987, 138:1464-1468.
6. Nair S.P., Meghji S., Wilson M., et al. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 1996, 64:2371-2380.
7. Delima A.J., Oates T., Assuma R., et al. Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol 2001, 28:233-240.
8. Seymour G.J., Ford P.J., Cullinan M.P., Leishman S., Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007, 13:3-10.
9. Kim J., Amar S. Periodontal disease and systemic conditions: a bidirectional relationship. Odontology 2006, 94:10-21.
10. Cianciola L., Park B., Bruck E., Mosorich L., Genco R.J. Prevalence of periodontal disease in insulin-dependent diabetes mellitus. J Am Dent Assoc 1982, 104:653-660.
11. Shlossman M., Knowler W.C., Pettitt D.J., Genco R.J. Type 2 diabetes mellitus and periodontal disease. J Am Dent Assoc 1990, 121:531-536.
12. Löe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 1993, 16:329-334.
13. Manouchehr-Pour M., Spagnuolo P.J., Rodman H.M., Bissada N.F. Comparison of neutrophil chemotactic response in diabetic patients with mild and severe periodontal disease. J Periodontol 1981, 52:410-414.
14. McMullen J.A., Van Dyke T.E., Horoszewicz H.U., Genco R.J. Neutrophil chemotaxis in individuals with advanced periodontal disease and a genetic predisposition to diabetes mellitus. J Periodontol 1981, 52:167-173.
15. Ramamurthy N.S., Golub L.M. Diabetes increases collagenase activity in extracts of rat gingiva and skin. J Periodontal Res 1983, 18:23-30.
16. Sasaki T., Ramamurthy N.S., Yu Z., Golub L.M. Tetracycline administration increases protein (presumably procollagen) synthesis and secretion in periodontal ligament fibroblasts of streptozotocin-induced diabetic rats. J Periodontal Res 1992, 27:631-639.
17. 2 shows stable interindividual differences. Scand J Immunol 1988, 27:705-716.
18. Salvi G.E., et al. Monocytic TNF-α secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol 1997, 24:8-16.
19. Salvi G.E., et al. Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin dependent diabetes mellitus patients. J Periodontal Res 1997, 68:127-135.
20. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1320.
21. Bucala R., et al. Modification of low density lipoprotein by AGEs contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994, 27:9441-9445.
22. Ruderman N., Williamson J., Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992, 6:2905-2914.
23. Schmidt A.M., et al. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997.
24. Neeper M., et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004.
25. Brett J., et al. Tissue distribution of the receptor for advanced glycation end products (RAGE): expression in smooth muscle, cardiac myocytes, and neural tissue in addition to the vasculature. Am J Pathol 1993, 143:1699-1712.
26. Schmidt A.M., Yan S.D., Stern D. The dark side of glucose (News and Views). Nat Med 1995, 1:1002-1004.
27. 2-Microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int 1998, 53:1365-1373.
28. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84:489-497.
29. Mosevitsky M.I., Novitskaya V.A., Iogannsen M.G., Zabezhinsky M.A. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem 1989, 185:303-310.
30. Lu J., Kobayashi R., Brill S.J. Characterization of a high mobility group 1/2 homolog in yeast. J Biol Chem 1996, 271:33678-33685.
31. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
32. Mullins G.E., Sunden-Cullberg J., Johansson A.S., et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol 2004, 60:566-573.
33. Wang H., Vishnubhakat J.M., Bloom O., et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392.
34. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
35. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
36. Taniguchi N., Kawahara K., Yone K., et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003, 48:971-981.
37. Park J.S., Svetkauskaite D., He Q., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
38. Kalinina N., Agrotis A., Antropova Y., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
39. Dumitriu I.E., Baruah P., Manfredi A.A., Bianchi M.E., Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 2005, 26:381-387.
40. Morimoto Y., Kawahara K.I., Tanchareon S., Kikuchi K., Maruyama I., et al. Tumor necrosis factor-α Stimulates Gingival Epithelial Cells to Release High-Mobility-Group Box 1. J Periodontal Res 2008, 43:76-83.
41. Feghali K., Iwasaki K., Tanaka K., Izumi Y., et al. Human gingival fibroblasts release high-mobility group box-1 protein through active and passive pathways. Oral Microbiol Immunol 2009, 24:292-298.
42. Volz H.C., Seidel C., Laohachewin D., Kaya Z., Andrassy M., et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 2010, 105:805-820.
43. Katz J., Bhattacharyya I., Farkhondeh-Kish F., Heft M.W., et al. Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol 2005, 32:40-44.
44. Son Y.H., Jeong Y.T., Lee K.A., Choi K.H., Kim K., et al. Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol 2008, 51(1):71-77.
45. Xiao Z.Y., Zhou W.X., Zhang Y.X., Yun L.H., et al. Inhibitory effect of linomide on lipopolysaccharide-induced proinflammatory cytokine tumor necrosis factor-alpha production in RAW264.7 macrophages through suppression of NF-κB, p38, and JNK activation. Immunol Lett 2007, 114(2):81-85.